Claudia R. Ball

This study develops an ex vivo drug sensitivity testing platform for rare solid tumors and finds that high in vitro sensitivity correlates with clinical benefit and progression-free survival.

This study identifies KAT2A as a therapeutic target in a subset of well-differentiated, microsatellite-stable colorectal cancers by showing its dependency and functional consequences.

The paper introduces pheno-seq, a method that links morphological features to gene expression in 3D cell cultures, showing its ability to identify morphology-specific genes and regulatory states not captured by scRNA-seq.